CYTEIR THERAPEUTICS, INC.

Inactive Instrument

Analyst Reco. Cyteir Therapeutics, Inc.

Equities

CYTT

US23284P1030

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Morgan Stanley Downgrades Cyteir Therapeutics to Underweight From Equal Weight, Adjusts Price Target to $2 From $4	23-02-03	MT
BofA Securities Downgrades Cyteir Therapeutics to Neutral From Buy, Adjusts Price Target to $2 From $4	23-01-30	MT
Wedbush Lowers Cyteir Therapeutics' Price Target to $3 From $8, Notes 'Disappointing' Monotherapy Results; Keeps Outperform Rating	23-01-23	MT
JPMorgan Downgrades Cyteir Therapeutics to Neutral From Overweight	23-01-20	MT
Wedbush Lowers Cyteir Therapeutics' PT to $8 From $13, Adjusts Expectations Around Future Equity Raises in Model; Keeps Outperform Rating	22-11-08	MT
Morgan Stanley Downgrades Cyteir Therapeutics to Equalweight From Overweight, Cuts Price Target to $4 From $14	22-09-09	MT
Wedbush Adjusts Price Target on Cyteir Therapeutics to $13 From $17, Keeps Outperform Rating	22-08-09	MT
Wedbush Adjusts Cyteir Therapeutics' Price Target to $17 From $30, Citing Future Equity Financings, CYT-0851 Mechanism Update; Outperform Rating Kept	22-04-28	MT
Wedbush Adjusts Cyteir Therapeutics' Price Target to $30 From $40, Citing Future Equity Raises; Outperform Rating Kept	22-03-17	MT
Northland Starts Cyteir Therapeutics at Outperform With $16 Price Target	22-02-07	MT
CYTEIR THERAPEUTICS : Wedbush Starts Cyteir Therapeutics at Outperform With $40 Price Target	21-07-13	MT
CYTEIR THERAPEUTICS : Morgan Stanley Starts Cyteir Therapeutics at Overweight With $33 Price Target	21-07-13	MT
CYTEIR THERAPEUTICS : BofA Securities Starts Cyteir Therapeutics at Buy With $23 Price Target	21-07-13	MT
CYTEIR THERAPEUTICS : JPMorgan Starts Cyteir Therapeutics at Overweight With $30 Price Target	21-07-13	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Like the pros, access all the transcripts and spot the best opportunities before anyone else.

Unlock them now!

fermer